Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Robert and Renée Belfer Center for Applied Cancer Science

  • David Barbie, MD, and Pasi Jänne, MD, PhD
  • Mission Statement

    The Belfer Center for Applied Cancer Science is an industry-inspired, self-sustaining scientific center within Dana-Farber Cancer Institute whose mission is the improvement of patient outcomes by discovering and advancing more efficacious cancer therapies.

    The Belfer Center for Applied Cancer Science is a fully integrated, collaborative cancer research center dedicated to translating today's most innovative oncology research into tomorrow's most promising cancer treatments.

    As part of the Dana-Farber Cancer Institute and affiliated with Harvard Medical School, the Belfer Center actively collaborates with two key groups of stakeholders in therapeutic oncology research:

    • Pharmaceutical and biotechnology companies seeking to bring basic and preclinical scientific breakthroughs to market in the form of new therapeutic products, such as small molecule drugs, biologics, and immunotherapies
    • Academic physician/scientists conducting basic and translational oncology research and clinical studies, and who care for patients with cancer on a daily basis

    The Belfer Center's strategic collaborations with leading pharmaceutical companies are driving the development of the next generation of cancer therapies. We are accelerating the development of new cancer treatment through work in the high-impact areas of:

    • Immuno-oncology
    • Drug resistance
    • Novel target discovery
    • Blood-based biomarkers

    Technologies and resources

    Our portfolio of unique technologies and resources exists to help academic and industry partners achieve preclinical success in developing and bringing to market novel therapeutics for cancer. Collaborations based on these technologies have:

    • Advanced drugs in clinical trials to help patients
    • Developed cancer therapies and novel combinations
    • Revealed novel insights into treating cancer
    • Conducted cutting-edge cancer research

    Platforms and capabilities

    Companies, investigators, and organizations that partner with the Belfer Center gain access to a suite of revolutionary platforms and capabilities that impact the success and efficiency of preclinical and early clinical oncology therapeutic development — from target identification to delineation of clinical path therapeutic agents, including data for IND submissions.

    With cutting-edge capabilities at their fingertips, Belfer investigators can help solve the most challenging scientific and drug development problems with rigor and efficiency.

    Our team

    At the Belfer Center, people are our strongest asset. The members of our scientific team are leaders in their respective fields. Together, they have a deep history of academic and industry research, development, and collaboration — always with the goal of translating basic, preclinical, and clinical insights into new advances in cancer biology and treatment.

    Organized into integrated research programs that leverage a broad network of Dana-Farber investigators and research centers of excellence, our people are at the forefront of developing the next generation of cancer therapies.

    Our leadership

    Pasi Janne, MD, PhD

    Pasi Jänne, MD, PhD
    Scientific Co-Director, Belfer Center for Applied Cancer Science
    Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

    David Barbie, MD

    David Barbie, MD
    Scientific Co-Director, Belfer Center for Applied Cancer Science
    Medical Oncologist, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

    Cloud Paweletz, PhD

    Cloud Paweletz, PhD
    Head of Research, Belfer Center for Applied Cancer Science

    Learn more about the Belfer Center — including details about the technologies and platforms available to our partners.

    Contact us to discuss partnership or collaboration opportunities.